Et utvalg vitenskapelige artikler basert GoTreatIT® Rheuma
Nowakowski, Jarosław et al. “Prevalence of cardiovascular comorbidities in psoriatic arthritis: relationship to clinical phenotype and treatment in a real-life study.” Polish archives of internal medicine, 16911. 2 Jan. 2025, doi:10.20452/pamw.16911
Guła, Zofia et al. “Higher serotonin levels among patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis compared to healthy controls assessed by liquid chromatography-tandem mass spectrometry (LC-MS).” Rheumatology international vol. 45,1 17. 3 Jan. 2025, doi:10.1007/s00296-024-05769-0
Guła, Zofia et al. “A comparison of comorbidities and their risk factors prevalence across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis with focus on cardiovascular diseases: data from a single center real-world cohort.” Rheumatology international vol. 44,12 (2024): 2817-2828. doi:10.1007/s00296-024-05740-z
Biedroń, Grzegorz et al. “Impact of comorbidities on patient-reported outcomes in psoriatic arthritis: a single centre cohort study.” Rheumatology international vol. 44,8 (2024): 1435-1443. doi:10.1007/s00296-024-05632-2
Guła, Zofia et al. “A comparison of comorbidities and their risk factors prevalence across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis with focus on cardiovascular diseases: data from a single center real-world cohort.” Rheumatology international vol. 44,12 (2024): 2817-2828. doi:10.1007/s00296-024-05740-z
Łosińska, Katarzyna et al. “Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab.” Rheumatology international vol. 43,5 (2023): 881-888. doi:10.1007/s00296-023-05307-4
Brkic, Alen et al. “Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010-2019).” BMC health services research vol. 23,1 968. 7 Sep. 2023, doi:10.1186/s12913-023-09975-7
Brkic, Alen et al. “Remission or Not Remission, That’s the Question: Shedding Light on Remission and the Impact of Objective and Subjective Measures Reflecting Disease Activity in Rheumatoid Arthritis.” Rheumatology and therapy vol. 9,6 (2022): 1531-1547. doi:10.1007/s40744-022-00490-5
Michelsen, Brigitte et al. “Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study.” Rheumatology and therapy vol. 9,4 (2022): 1171-1179. doi:10.1007/s40744-022-00464-7
Łosińska, Katarzyna et al. “Long-term drug effectiveness and survival for reference rituximab in rheumatoid arthritis patients in an ordinary outpatient clinic.” Scientific reports vol. 12,1 8283. 18 May. 2022, doi:10.1038/s41598-022-12271-9
Michelsen, Brigitte et al. “Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of standard care.” PloS one vol. 17,5 e0266816. 5 May. 2022, doi:10.1371/journal.pone.0266816
Wilk, Mateusz et al. “Pain catastrophizing in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: biopsychosocial perspective and impact on health-related quality of life.” Rheumatology international vol. 42,4 (2022): 669-682. doi:10.1007/s00296-021-05070-4
Brkic, Alen et al. “Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010-2019 – a country with a national tender system for prescription of costly drugs.” BMC health services research vol. 22,1 48. 10 Jan. 2022, doi:10.1186/s12913-021-07425-w
Thomsen, Ruth Stoklund et al. “Effect of high-intensity interval training on cardiovascular disease risk factors and body composition in psoriatic arthritis: a randomised controlled trial.” RMD open vol. 4,2 e000729. 11 Oct. 2018, doi:10.1136/rmdopen-2018-000729
Ikdahl, Eirik et al. “Feasibility of cardiovascular disease risk assessments in rheumatology outpatient clinics: experiences from the nationwide NOCAR project.” RMD open vol. 4,2 e000737. 1 Oct. 2018, doi:10.1136/rmdopen-2018-000737
Haugeberg, Glenn et al. “Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway.” Arthritis research & therapy vol. 20,1 160. 2 Aug. 2018, doi:10.1186/s13075-018-1659-z
Michelsen, Brigitte et al. “Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.” The Journal of rheumatology vol. 44,4 (2017): 431-436. doi:10.3899/jrheum.160973
van Riel, Piet et al. “Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools.” RMD open vol. 2,2 e000302. 24 Nov. 2016, doi:10.1136/rmdopen-2016-000302
Sokka, Tuulikki. “Go, go, GoTreatIT!.” Clinical and experimental rheumatology vol. 34,5 Suppl 101 (2016): S91-S95.
Väre, Paula et al. “Delivering a one-stop, integrated, and patient-centered service for patients with rheumatic diseases.” SAGE open medicine vol. 4 2050312116654404. 14 Jun. 2016, doi:10.1177/2050312116654404
Haugeberg, Glenn et al. “Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway.” Arthritis research & therapy vol. 17,1 219. 20 Aug. 2015, doi:10.1186/s13075-015-0716-0
Michelsen, Brigitte et al. “A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.” PloS one vol. 10,4 e0123582. 8 Apr. 2015, doi:10.1371/journal.pone.0123582
